|Other Names||Transcription factor AP-1, Activator protein 1, AP1, Proto-oncogene c-Jun, V-jun avian sarcoma virus 17 oncogene homolog, p39, JUN|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP3295a was selected from the region of human Phospho-JUN-T249. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells (PubMed:24623306). Binds to the USP28 promoter in colorectal cancer (CRC) cells (PubMed:24623306).|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene for the cJun protein is the putative transforming gene of avian sarcoma virus 17. The protein is highly similar to the viral protein, and interacts directly with specific target DNA sequences to regulate gene expression. The gene for this protein is intronless and is mapped to 1p32-p31, a chromosomal region involved in both translocations and deletions in human malignancies.
Fang, D., et al., Proc. Natl. Acad. Sci. U.S.A. 101(41):14782-14787 (2004).Wang, Y., et al., Biochem. Biophys. Res. Commun. 323(1):9-16 (2004).Wehkamp, J., et al., Infect. Immun. 72(10):5750-5758 (2004).Gensch, E., et al., J. Biol. Chem. 279(37):39085-39093 (2004).Fujioka, S., et al., Mol. Cell. Biol. 24(17):7806-7819 (2004).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.